Effect of Shenyuan Granules on serum fibroblast growth factor 23, fibroblast growth factor receptor 4 and Klotho protein in non-dialysis patients with chronic kidney disease of stage 3-5
CHENG Hong1,2 ZOU Xinrong1,2 LI Yingxia3 WANG Xiaoqin1,2
1.Department of Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Institute of Nephrology, Hubei Institute of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China;
3.the First Clinical College, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430061, China
Abstract：Objective To observe the effect of Shenyuan Granules on the serum fibroblast growth factor 23 (FGF 23), fibroblast growth factor receptor 4 (FGFR 4) and Klotho protein in non-dialysis patients with chronic kidney disease (CKD) of stage 3-5, so as to explore the possible mechanism of Shenyuan Granules on vascular calcification in CKD patients. Methods A total of 60 patients with CKD admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from June 2018 to June 2019 were selected and they were divided into the control group (28 cases) and the treatment group (32 cases) by random number table method. The control group was treated with Niaoduqing Granules, while the treatment group was treated with Shenyuan Granules. After 3 months of continuous treatment, the levels of biochemical indexes (serum calcium, phosphorus, parathyroid hormone [PTH] and estimated glomerular filtration rate [GFR]), and serum FGF23, FGFR4 and Klotho protein content were observed before and after treatment. Results Before treatment, there were no statistically significant differences in calcium, phosphorus, PTH and eGFR between the two groups (P > 0.05). After treatment, serum phosphorus and PTH in the treatment group were lower than those inthe control group, while calcium and eGFR were higher than that in the control group, with statistically significant differences (all P < 0.05). Before treatment, there was no significant difference in FGF23, FGFR4, and Klotho protein content between the two groups (P > 0.05). After treatment, serum FGF23 and Klotho protein content in the treatment group were higher than those in the control group, and FGFR4 content was lower than that in the control group, with statistically significant differences (all P < 0.05). Conclusion Shenyuan Granules can inhibit FGF23 and FGFR4 levels and increase Klotho protein content, which may be one of the mechanisms of Shenyuan Granules in the treatment of vascular calcification in patients with CKD.
程虹1,2 邹新蓉1,2 李颖霞3 王小琴1,2. 肾元颗粒对慢性肾脏病3~5期非透析患者血清成纤维细胞生长因子23、成纤维细胞生长因子受体4、Klotho蛋白的影响[J]. 中国医药导报, 2020, 17(28): 125-128.
CHENG Hong1,2 ZOU Xinrong1,2 LI Yingxia3 WANG Xiaoqin1,2. Effect of Shenyuan Granules on serum fibroblast growth factor 23, fibroblast growth factor receptor 4 and Klotho protein in non-dialysis patients with chronic kidney disease of stage 3-5. 中国医药导报, 2020, 17(28): 125-128.
[1] Ware T. Chronic kidney disease [J]. InnovAIT，2018，11（1）：35-40.
[2] Singh P，Chandola V，Fox C. Automatic Extraction of Deep Phenotypes for Precision Medicine in Chronic Kidney Disease[C]//Proceedings of the 2017 international Conference on Digital Health，2017：195-199.
[3] Sepanlou SG，Barahimi H，Najafi I，et al. Prevalence and determinants of chronic kidney disease in northeast of Iran： Results of the Golestan cohort study[J]. PLoS One，2017，12（5）：e0176540.
[4] Levin A，Tonelli M，Bonventre J，et al. Global kidney health 2017 and beyond： a roadmap for closing gaps in care，research，and policy[J]. Lancet，2017，390（10105）：1888-1917.
[5] 饶向荣.慢性肾脏病的中西医结合防治[J].中国中西医结合杂志，2019，39（7）：781-783.
[6] 庄振起，周广宇，尹敏，等.尿毒清治疗慢性肾脏病的基础和临床研究进展[J].中成药，2015，37（11）：151-154.
[7] 邓惠文.肾元颗粒治疗慢性肾脏病3-5期临床观察[D].武汉：湖北中医药大学，2019.
[8] Yuan J，Zou XR，Han SP，et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients：results from the Chinese cohort study of chronic kidney disease （C-STRIDE）[J]. BMC Nephrol，2017， 18（1）：23.
[9] Kidney Disease：Improving Global Outcomes（KDIGO）CKD-MBD Update Work Group.KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis，Evaluation，Prevention，and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder（CKD-MBD）[J]. Kidney Int Suppl，2017， 7：1-59.
[10] 梁萌.慢性肾脏病钙磷代谢紊乱的防治（摘要）[C]//中国中西医结合学会肾脏疾病专业委员会2018年学术年会.
[11] 张家珍，邹新蓉，王小琴，等.慢性肾脏病非透析患者钙磷代谢紊乱的相关性分析[J].华南国防医学杂志，2016， 30（5）：312-315.
[12] Dobenecker B，Webel A，Reese S，et al. Effect of a high phosphorus diet on indicators of renal health in cats [J]. J Feline Med Surg，2018，20（4）：339-343.
[13] Suki WN，Moore LW. Phosphorus regulation in chronic kidney disease [J]. Methodist Debakey Cardiovasc J，2016， 12（4 Suppl）： 6-9.
[14] Wahl P，Wolf M. FGF23 in chronic kidney disease [M]//Endocrine FGFs and Klothos. Springer，New York，NY，2012：107-125.
[15] Kuro-O M. Klotho and endocrine fibroblast growth factors：markers of chronic kidney disease progression and cardiovascular complications?[J]. Nephrol Dia Transplant，2019，34（1）：15-21.
[16] Freedman BI，Divers J，Ｒussell GB，et al． Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus [J]. Am J Nephrol，2015，42（6）：391-401.
[17] Sugiura H，Matsushita A，Futaya M，et al. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model [J]. PLoS One，2018，13（3）：e0191706.
[18] Grabner A，Schramm K，Silswal N，et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible [J]. Sci Rep，2017，7（1）：1993.
[19] Singh S，Grabner A，Yanucil C，et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease [J]. Kidney Int，2016， 90（5）：985-996.
[20] Grabner A，Amaral AP，Schramm K，et al. Activation of Cardiac Fibroblast Growth Factor Receptor4 Causes Left Ventricular Hypertrophy [J]. Cell Metab，2015，22（6）：1020-1032.
[21] Maren LN，Siemer RG，Flasbart K，et al. Induction of cardiac FGF23/FGFＲ4 expression is associated with left ventricular hy-pertrophy in patients with chronic kidney disease[J]．Nephrol Dial Transpl，2016，31（7）：1088-1099．
[22] Kim HJ，Kang E，Oh YK，et al. The association between soluble klotho and cardiovascular parameters in chronic kidney disease：Results from the KNOW-CKD study [J]. BMC Nephrol，2018，19（1）：51.
[23] 邱忆，王金艳，钟爱民，等.Klotho在诊治肾脏疾病中的应用进展[J].江西医药，2018，53（12）：145-148.
[24] 王岚，朱国双，孙龙，王小琴.肾元颗粒对db/db糖尿病肾病小鼠血管钙化的改善作用及其机制[J].吉林大学学报：医学版，2020，46（3）：431-438，669.
[25] 邹新蓉，王小琴，周全.肾安颗粒对5/6肾切除模型大鼠骨代谢的影响[J].中国实验方剂学杂志，2016，22（4）：106-109.
2020, Vol. 17 
京公网安备 11010502046598号